Trial · NCT01618695
Participant flow28
How many started, completed or left each group, period by period.
1 to 20 of 28
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Core Phase | STARTED | Core Phase: Placebo; Extension Phase: up to 12 mg Perampanel | 177 | |
| Core Phase | STARTED | Core Phase: Perampanel 4 mg; Extension Phase: up to 12 mg Perampanel | 176 | |
| Core Phase | STARTED | Core Phase: Perampanel 8 mg; Extension Phase: up to 12 mg Perampanel | 177 | |
| Core Phase | STARTED | Core Phase/Extension Phase: up to 12 mg Perampanel | 180 | |
| Core Phase | Treated (Safety Analysis Set) | Core Phase: Placebo; Extension Phase: up to 12 mg Perampanel | 176 | |
| Core Phase | Treated (Safety Analysis Set) | Core Phase: Perampanel 4 mg; Extension Phase: up to 12 mg Perampanel | 176 | |
| Core Phase | Treated (Safety Analysis Set) | Core Phase: Perampanel 8 mg; Extension Phase: up to 12 mg Perampanel | 175 | |
| Core Phase | Treated (Safety Analysis Set) | Core Phase/Extension Phase: up to 12 mg Perampanel | 180 | |
| Core Phase | COMPLETED | Core Phase: Placebo; Extension Phase: up to 12 mg Perampanel | 152 | |
| Core Phase | COMPLETED | Core Phase: Perampanel 4 mg; Extension Phase: up to 12 mg Perampanel | 156 | |
| Core Phase | COMPLETED | Core Phase: Perampanel 8 mg; Extension Phase: up to 12 mg Perampanel | 147 | |
| Core Phase | COMPLETED | Core Phase/Extension Phase: up to 12 mg Perampanel | 144 | |
| Core Phase | NOT COMPLETED | Core Phase: Placebo; Extension Phase: up to 12 mg Perampanel | 25 | |
| Core Phase | NOT COMPLETED | Core Phase: Perampanel 4 mg; Extension Phase: up to 12 mg Perampanel | 20 | |
| Core Phase | NOT COMPLETED | Core Phase: Perampanel 8 mg; Extension Phase: up to 12 mg Perampanel | 30 | |
| Core Phase | NOT COMPLETED | Core Phase/Extension Phase: up to 12 mg Perampanel | 36 | |
| Extension Phase | STARTED | Core Phase: Placebo; Extension Phase: up to 12 mg Perampanel | 151 | |
| Extension Phase | STARTED | Core Phase: Perampanel 4 mg; Extension Phase: up to 12 mg Perampanel | 156 | |
| Extension Phase | STARTED | Core Phase: Perampanel 8 mg; Extension Phase: up to 12 mg Perampanel | 146 | |
| Extension Phase | STARTED | Core Phase/Extension Phase: up to 12 mg Perampanel | 143 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01618695/flow